Systems and methods of reducing artifact in neurological stimulation systems

Information

  • Patent Grant
  • 8295934
  • Patent Number
    8,295,934
  • Date Filed
    Tuesday, November 14, 2006
    18 years ago
  • Date Issued
    Tuesday, October 23, 2012
    12 years ago
Abstract
The present invention relates to neurological systems and methods of use which acquire physiological signals from a subject and stimulate the subject. The system is adapted to control the timing at which the system acquires the physiological signals from the subject and the timing of the stimulation signal to reduce the amount of stimulation induced artifact that is acquired by the system.
Description
CROSS-REFERENCE

This application is related to commonly owned U.S. Pat. No. 6,366,813, filed Jun. 25, 1999 and U.S. Pat. No. 6,819,956, filed Nov. 11, 2001.


This application is also related to commonly owned U.S. patent application Ser. Nos. 11/321,897 and 11/322,150, both filed Dec. 28, 2005


BACKGROUND OF THE INVENTION

The present invention relates generally to reducing artifacts in a sampled physiological signal from a subject. More specifically, the present invention relates to methods and systems for delivering stimulation in separate epochs of time from data acquisition epochs of time.


Closed loop neurological stimulation systems that acquire physiological signals from a subject and stimulate a subject can produce stimulation-induced artifact signals when the acquisition of the physiological signal from the subject and stimulation of the subject occur substantially at the same time.


For example, electroencephalographic (EEG) signals acquired from subjects are small in amplitude and relatively low in frequency. Scalp EEG signals, for example, have amplitudes on the order of about 10 uV to about 100 uV and have frequency content in the range of about 0.1 to about 70 Hz. Electrocorticography (ECoG) is the practice of recording signals directly from the surface of the cerebral cortex. ECoG signals are larger, in the range of about 10 uV to about 1000 uV, and depending on the size and geometry of the measuring electrode, which may vary from a disk contact several mm in diameter to a needle-like micro-electrode with dimensions on the orders of microns, these signals may contain useful information at frequencies from 0.01 Hz up to up to several hundred Hz. In practice, the term EEG or intracranial EEG is often used in place of the term ECoG; for simplicity we will use the term “EEG” throughout the remainder of this document to encompass both intracranial EEG and scalp EEG.


Electrical stimulation signals used to stimulate nerve cells are typically similar in frequency to EEG signals but can be much larger in amplitude. Typical stimulation frequencies, or pulse repetition frequencies, range from about 1 Hz to about 1000 Hz. Stimulation pulse widths are typically on the order of about 50 us to about 500 us. Pulse shapes are typically rectangular rather than smoothed or sinusoidal, and therefore generate significant amount of energy at harmonics of the pulse repetition frequency. Typical stimulation waveform amplitudes may be in the range of about 1 V to about 10 V, and when coupled to stimulating electrodes with typical electrode impedances of about 500 Ohms to about 2000 Ohms, this leads to stimulation current amplitudes of between about 0.5 mA and about 20 mA. In order to avoid damage to neural tissue or to the stimulating electrodes, the charge per stimulation pulse should be limited to below about 100 uC to about 200 uC per square cm of electrode area.


A stimulation signal may cause artifact when sensed at substantially the same time as a physiological signal because the electrical stimulation signal can be substantially larger and in substantially the same frequency band as the physiological signal (e.g., an EEG signal).


Stimulation-induced artifact can be reduced by filtering out the artifact signal. Some existing technologies may also synchronize the timing of the filtering process with the timing of the stimulation signal in order to reduce stimulation-induced artifact. These systems, however, do not control the time at which the signal acquisition and stimulation occur, but rather rely on filtering out the artifact signal after it has already been acquired. In addition, some systems simply disable the detection device while stimulation occurs.


There remains a need for a neurological stimulation system which acquires physiological signals from a subject and stimulates the subject to reduce the amount of stimulation-induced artifact sensed by the system.


SUMMARY OF THE INVENTION

One aspect of the invention is a system to reduce artifact in a signal acquired from a subject. The system includes a sensing assembly adapted to acquire a signal from a subject indicative of the subject's brain activity, a stimulation assembly adapted to stimulate one or more neurons of the subject, and a timing controller programmed to control the time at which the sensing assembly acquires the signal to be substantially different than when the stimulation assembly stimulates the subject.


In some embodiments of the system the timing controller is programmed to control the time at which the sensing assembly acquires the signal to be multiple discrete acquisition times and to control the time at which the stimulation assembly stimulates the one or more neurons to be multiple discrete stimulation times. The timing controller can be programmed to control the sensing assembly to acquire the signal in between the stimulation assembly stimulating the one or more neurons. In some embodiments the multiple discrete acquisition times and multiple discrete stimulation times each occur in a regular pattern. In some embodiments the acquisition times and the stimulation times provide epochs of time between the acquisition times and stimulation times in which no acquisition or stimulation occurs.


In some embodiments the multiple discrete acquisition times are about 0.25 seconds to about 5 minutes. In some embodiments the multiple discrete acquisition times are about 5 seconds.


In some embodiments the multiple discrete stimulation times are about 0.5 seconds to about 5 minutes. In some embodiments the multiple discrete acquisition times are about 20 seconds.


In some embodiments the sensing assembly and the stimulation assembly each comprise an electrode array. The same electrode array can be used to stimulate the one or more neurons and acquire the signal from the subject. In some embodiments the stimulation assembly comprises an electrode array adapted to be coupled to a peripheral nerve. In some embodiments the peripheral nerve is a vagus nerve.


In some embodiments the signal is an EEG signal from the subject.


In some embodiments the system further comprises a control assembly adapted to adjust the multiple discrete acquisition times and the multiple discrete stimulation times. The control assembly can be in communication with a device external to the subject wherein the device is adapted to allow adjustment of the stimulation and acquisition times. In some embodiments the control assembly is adapted to dynamically adjust the stimulation or acquisition times.


In some embodiments of the system the subject's brain activity is analyzed to predict an onset of a seizure.


In some embodiments the system also includes a signal processor in communication with the sensing assembly adapted to process the signal to estimate an epileptic neural state. The signal processor can comprise an observer algorithm operative when the sensing assembly is acquiring the signal. In some embodiments the observer algorithm comprises one or more feature extractors and a classifier.


Another aspect of the invention is a method of reducing artifact in a signal acquired from a subject. The method comprises acquiring a signal from a subject indicative of the subject's brain activity, stimulating the subject, and controlling the time at which the acquiring the signal occurs to be substantially different than the stimulating the subject.


In some embodiments the acquiring comprises acquiring the signal at multiple discrete acquisition times and the stimulating comprises stimulating the one or more neurons at multiple discrete stimulation times. The acquiring the signals can occur between the stimulating the subject. In some embodiments the acquiring and stimulating each occur in a regular pattern.


In some embodiments the multiple discrete acquisition times are about 0.25 seconds to about 5 minutes. In some embodiments the multiple discrete acquisition times are about 5 seconds.


In some embodiments the multiple discrete stimulation times are about 0.5 seconds to about 5 minutes. In some embodiments the multiple discrete stimulation times are about 20 seconds.


In some embodiments the acquiring comprises acquiring an EEG signal from the subject. In some embodiments the stimulating comprises stimulating a peripheral nerve such as a vagus nerve.


In some embodiments the method further comprises adjusting the multiple discrete acquisition times and/or the multiple discrete stimulation times.


In some embodiments the subject's brain activity is processed to measure the subject's susceptibility to a seizure.


In some embodiments the method further comprises processing the signal to estimate an epileptic neural state.


Another aspect of the invention is a method of managing seizures. The method comprises acquiring an EEG signal from a subject during multiple discrete acquisition times occurring in a regular pattern, stimulating one or more neurons of the subject during multiple discrete stimulation times occurring in a regular pattern, and controlling the times at which the acquiring the EEG signal occurs to be substantially different than the stimulating the one or more neurons of the subject.


Incorporation By Reference

All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.





BRIEF DESCRIPTION OF THE DRAWINGS

The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:



FIG. 1 illustrates a sensing assembly, timing controller, and stimulation assembly.



FIG. 2 illustrate two examples of electrode arrays that may be used with a system of the present invention.



FIG. 3 shows a timeline showing acquisition and stimulation epochs and an exemplary Period of stimulation of the present system.



FIG. 4 illustrates an acquisition duty cycle.



FIG. 5 shows a duty cycling method with a seizure prediction/detection algorithm.



FIG. 6 shows an exemplary system of the present invention.



FIG. 7 shows components of an implanted unit and components of an external device.





DETAILED DESCRIPTION OF THE INVENTION

The systems of the present invention generally reduce artifact in a signal, e.g., an electrical signal, acquired from a subject. In particular, the system can reduce stimulation-induced artifact sensed with a neurological stimulation system that is at least partially implanted in a subject. One aspect of the invention is a system that comprises a sensing assembly adapted to acquire a signal from a subject that contains data that is indicative of the subject's brain activity state or neural state, a stimulation assembly adapted to stimulate one or more neurons of a nervous system component of the subject, and a timing controller programmed to control the time of acquiring the signal(s) from the subject and delivering electrical stimulation to the subject.


The present invention can reduce artifact in the acquired signal by controlling the time at which the signal is acquired from the subject to be substantially different than the time at which the subject is stimulated. Controlling the timing of the signal acquisition and stimulation can reduce the amount of stimulation signal that is sensed by the sensing assembly, thus reducing artifact signals. Furthermore, as data acquisition and stimulating requires the use of power, which may be limited in an implantable neurological stimulation system, controlling the sensing assembly and stimulation assembly to acquire a signal and stimulate at specific times, rather than sensing and stimulating continuously, allows for a more efficient use of the system's power supply.


The methods of the present invention are applicable to closed-loop control systems for controlling a subject's state, closed-loop detection and prediction systems that are used to detect and/or predict the onset of neurological events, and other closed-loop systems which acquire data and deliver a neuromodulation signal to the subject. Each of such systems will typically include one or more algorithms for analyzing signals from the subject and/or determining the subject's response to the analyzed signals. Such algorithms will be referred to herein collectively as an “observer algorithm.”


While the remaining discussion focuses on closed-loop control of seizures and detecting and/or predicting an onset of seizures, the present invention may be equally applicable to monitoring and treatment of other neurological and non-neurological conditions. For example, some other conditions that may be treated using the systems of the present invention include, but is not limited to, Alzheimer' disease, Parkinson's disease, migraine headaches, sleep apnea, Huntington's disease, hemiballism, choreoathetosis, dystonia, akinesia, bradykinesia, restless legs syndrome, other movement disorder, dementia, depression, mania, bipolar disorder, other affective disorder, motility disorders, anxiety disorder, phobia disorder, borderline personality disorder, schizophrenia, multiple personality disorder, and other psychiatric disorder, Parkinsonism, rigidity, or hyperkinesias, substance abuse, attention deficit hyperactivity disorder, impaired control of aggression, impaired control of sexual behavior, or the like.



FIG. 1 shows an exemplary system 2 including a timing controller 4 in communication with a sensing assembly 6 and a stimulation assembly 8. The sensing assembly is generally adapted to acquire a signal from a subject which is indicative of the subject's brain activity or the subject's neural state. The term “neural state” is used herein to generally refer to calculation results or indices that are reflective of the state of the subject's neural system, but does not necessarily constitute a complete or comprehensive accounting of the subject's total neurological condition. The estimation and characterization of “neural state” may be based on one or more subject dependent parameters from the brain, such as electrical signals from the brain. In preferred embodiments the sensing assembly is coupled to at least one electrode array to acquire the electrical signal from the subject.


While the electrode arrays may be implanted anywhere within the subject's body, preferred electrode arrays include intracranial or extracranial EEG electrode arrays. The EEG electrode arrays can be adapted to be placed on the subject's head, implanted under the skin, screwed into the skull, or implanted intracranially. For example, in minimally invasive embodiments the electrode array can be implanted beneath at least one layer of the scalp, above the subject's cranium/calvarium, and over one or more target area of the subject's brain. The electrode array may be implanted between any of the layers of the scalp. For example, the electrode array may be positioned between the skin and the connective tissue, between the connective tissue and the epicranial aponeurosis/galea aponeurotica, between the epicranial aponeurosis/galea aponeurotica and the loose aerolar tissue, between the loose aerolar tissue and the pericranium, and/or between the pericranium and the calvarium. In some configurations, it may be useful to implant different electrode arrays between different layers of the scalp.


In more invasive embodiments the electrode array of the sensing assembly includes an intracranial (IC) recording electrode array (e.g., epidural, subdural, depth electrodes, etc.) or a bone screw array which samples intracranial neural signals, including but not limited to cortical, white matter, and deep brain signals. Neural activity to be sensed includes but is not limited to that found in the primary motor cortex, premotor cortex, supplementary motor cortex, somatosensory cortex, white matter tracts associated with these cortical areas, the globus pallidus internal segment, the globus pallidus external segment, the caudate, the putamen, and other cortical and subcortical areas.


The EEG electrode arrays used with the system 2 may include any number of electrodes, and can be placed at a variety of locations in or on the subject such that an EEG signal can be acquired from the subject. The EEG electrode array typically includes between about 8 electrodes and 64 electrodes, but may have more or less, as desired. Some useful electrode arrays include a 1×8 electrode strip, a 2×4 electrode grid, a 3×3 grid array, a 1×8 depth electrode array, an array of bone screws, sphenoidal electrode array, and a nerve cuff electrode array, but many other configurations and types of electrodes may also be useful with the system.


While EEG electrode arrays are one currently preferred embodiment, other types of electrode arrays may also be used in addition to or as an alternative to the EEG electrode arrays. For example, the electrode arrays may include any of the following types of electrodes, either alone or in combination with each other, an electromyography (EMG) array for acquiring EMG signals, an accelerometer array for acquiring acceleration signals, an acoustic transducer array, a peripheral nerve electrode array (e.g., vagus nerve), a cranial nerve electrode array (e.g., trigeminal nerve) or other biological sensors or electrodes for monitoring blood pressure, pulse oximetry, temperature of the brain or other portion of the subject, blood flow measurements in the brain or other parts of the body, ECG/EKG, heart rate signals and/or change in heart rate signals, respiratory rate signals and/or change in respiratory rate signals, chemical concentrations of neuro transmitters, chemical concentrations of medications, pH in the blood or other portions of the body, other vital signs, other physiological or biochemical parameters of the subject's body, or the like.


For example, as noted above, another type of sensing electrode array that may be used with the system is a peripheral nerve electrode array which may be used to acquire peripheral neural signals, including but not limited to efferent and afferent axonal signals from a vagus nerve. The single or plurality of individual peripheral nerve electrode arrays which comprise peripheral nerve electrode array may be implanted in any number of locations throughout the subject. Such peripheral nerve electrode arrays may also be used to deliver a stimulation output signal to the subject. Additional electrode arrays which can also be included in the sensing assembly can be found in commonly owned U.S. Pat. No. 6,366,813, which issued Apr. 2, 2002.


Data acquisition and stimulation may be performed using different sets of electrode arrays, the same sets of electrode arrays, or a mixed set of electrodes within the arrays. For example, FIG. 2 shows two exemplary electrode arrays that may be used with the system 2. Electrodes A-H are positioned on a 2×4 grid array 9 and electrodes I-P are positioned on a 1×8 strip electrode array 11. Such electrode arrays may be placed subdurally or epidurally. In some embodiments, the electrode arrays will be positioned over a seizure focus to receive electrical signals from the seizure focus. In many embodiments, it may also be desirable to also deliver electrical stimulation to the same seizure focus. As such, it may be desirable to use the same electrode arrays to both sense and deliver stimulation.


In other configurations it may be desirable to use one electrode array 9 (e.g., electrodes A-H) to sense signals and to use electrode array 11 (e.g., electrodes I-P) to deliver stimulation to the subject. In yet other configurations it may be desirable to use some or all of the electrodes on arrays 9, 11 to sense and to use some or all of the electrodes to deliver stimulation. For example, it may be desirable to use a mixed set of electrodes to sense and stimulate. For example, electrodes A-H of array 9 may be used to sense signals and electrodes B-C-F-G may be used to deliver electrical stimulation. Similarly, electrodes I-M of array 11 may be used to sense signals and electrodes L-P may be used to deliver electrical stimulation.


The systems of the present invention typically include one or more implantable devices or components and one or more external devices or components. However, in other embodiments, the entire system may be implantable within the subject. Any number of the system components can be adapted to be implantable or external to the subject.


The signals sensed by sensing assembly 6 are typically reflective of the subject's brain activity state and/or neural state. Analysis of the brain activity state by the observer algorithm may indicate that the subject is in an inter-ictal state (e.g., a normal state) in which the subject has a low susceptibility to a seizure, a pro-ictal state (e.g., a state that has an increased susceptibility to a seizure), a pre-ictal state (e.g., a state that indicates that a seizure is imminent), an ictal state (e.g., a state in which a seizure is already occurring) or a post-ictal state (e.g., a seizure has ended). As will be described in more detail below, it may be desirable to use such determinations of brain state to modify one or more parameters of the duty cycling, stimulation parameters and/or sensing parameters.


System 2 may be used with closed-loop control systems that are adapted to control the subject's neural state so as to substantially prevent the subject from entering a neural state in which the subject has an elevated susceptibility to a seizure. Delivery of electrical stimulation may be used to maintain the subject's neural state in a state that is at low susceptibility or in cases in which the subject has entered a neural state that has an elevated susceptibility to a seizure, to drive the subject's neural state from the elevated susceptibility to a seizure back down to a neural state that is at a low susceptibility to a seizure.


In order to provide stimulation and sensing of the subject's state, preferred embodiments of the system 2 comprise a timing controller 4 which may be programmed to control the time at which the sensing assembly 6 acquires the signal to be substantially different than the time when the stimulation assembly 8 stimulates the subject. In preferred embodiments the timing controller 4 is in communication with both the sensing assembly and the stimulating assembly, as shown in FIG. 1.


In some embodiments the timing controller 4 is programmed to control the time at which the sensing assembly 6 acquires the signal to be multiple discrete acquisition times and/or to control the time at which the stimulation assembly 8 stimulates the nervous system component to be multiple discrete stimulation times. The multiple discrete acquisition and stimulation times can be of any number and may be of any duration.



FIG. 3 illustrates an exemplary amplitude v. time graph showing multiple discrete acquisition epochs 10 and multiple discrete stimulation epochs 12. As shown in FIG. 3, the timing controller can be programmed to control the sensing assembly to acquire the signal in epochs between the stimulation epochs. Also shown in FIG. 3 are epochs of time 14 in between the acquisition epochs and stimulation epochs in which no acquisition or stimulation occurs. As can be seen from FIG. 3, the epochs at which stimulation occurs does not overlap with the epochs at which the acquisition occurs and thus stimulation-induced artifact, or stimulation signal that is sensed by the sensing assembly, is reduced. The system's power consumption can also be minimized by controlling the times at which the system acquires a signal from, and stimulates, the subject.


In some embodiments the timing controller can be programmed to control either the multiple discrete acquisition epochs and/or the multiple discrete stimulation epochs to occur in a regular pattern or adaptively. For example, the multiple discrete acquisition and or stimulation times can occur on a regular cycle or Period, as shown in FIG. 3. While FIG. 3 illustrates an “amplitude” of the stimulation epochs and sensing epochs as being constant, the parameters of the stimulation and sensing epochs may vary from period-to-period, epoch-to-epoch, or the like. The selection of parameters for each of the epochs may be based on a predetermined schedule, based on an analysis of the previously sensed signals from one or more previous epochs, or the like. For example, if the sensed signals are indicative of a neural state that is at an elevated susceptibility of a seizure, the parameters of the sensing within the sensing epoch may be changed (e.g., frequency of sampling EEG signals, duration of the sensing epochs, duration of the epochs between the sensing and stimulation, number of electrode channels being sampled, pre-amplification gain and bandwidth changes, or the like) and/or parameters of stimulation delivered during the stimulation epoch (e.g., duration of stimulation epoch, amplitude, current, voltage, pulse amplitude, pulse width, pulse frequency, pulses per burst, burst frequency, or the like) may be changed.


Some subjects are more prone to having seizures at specific times of day. Consequently, the timing controller may be programmed to automatically adjust the acquisition epochs and stimulation epochs based on time of day. For example, if the subject was known to have a particular vulnerability upon awakening from sleep, the timing controller could be configured to increase a duty cycle of sensing epochs in the morning hours.


In addition to the modification of the parameters within the epochs, the Period of the stimulation signal (as shown in FIG. 3) can also be increased or decreased. The increase or decrease of the Period of the stimulation signal may be based on processing of any of the previous acquisition epochs. For example, if the sensed signals are indicative of a neural state that is at an elevated susceptibility of a seizure, the Period of stimulation may be decreased in an attempt to quickly return the neural state to a more “normal” state (e.g., the stimulation epochs or parameters of the stimulation may be increased and the stimulation epochs of the sensing may be decreased).


The scheduling of acquisition epochs and/or the stimulation epochs may be based on a duty cycle. Duty cycle as used herein refers to the ratio of the duration of the event in a given Period to the Period. As shown in FIG. 4, the duty cycle of the acquisition times is given as the duration of the event “d” divided by the Period “T” of the event, or d/T. The acquisition and/or stimulation duty cycle can be varied as necessary according to the purposes of the invention. The Period of the stimulation signal as shown in FIG. 3 is 60 seconds In FIG. 3, the duty cycle of the stimulation signal is 5/60. The duty cycle can be increased, e.g., by increasing the value of “d,” while maintaining a constant value of “T,” or by maintaining a constant value of “d” and decreasing the value of “T.” Similarly, the duty cycle can be decreased.


The lengths of the data acquisition epochs, stimulation epochs and Period may vary from subject to subject and may vary based on the particular disorder being treated. For example, for treating epilepsy, the acquisition epoch is typically between about 0.25 seconds to about 5 minutes, preferably between about 1 second to about 30 seconds, and more preferably about 5 seconds. The stimulation epochs are typically between about 0.5 seconds to about 5 minutes, preferably between about 1 seconds and about 30 seconds, and most preferably about 20 seconds. As noted above, in some embodiments it may be desirable to have epochs of time between the data acquisition and stimulation epochs in which the system does not acquire signal from or deliver stimulation to the subject. The duration of these epochs of time is typically between 0.25 seconds and about 10 seconds, preferably between about 1 seconds and about 5 seconds, and most preferably about 4 seconds, but the length of such epochs may depend on the recovery of electrodes from voltage offsets caused by stimulation activity and/or by the acquisition and/or stimulation time programmed into the timing controller.


The duty cycling methods described above are equally applicable to systems whose observer algorithms are adapted for seizure prediction and seizure detection. In the seizure prediction/detection systems, neuromodulation (e.g., electrical stimulation) may only be delivered to the subject when it is determined that the subject has an elevated susceptibility for a seizure (e.g., a seizure is predicted). As shown in FIG. 5, such systems will acquire brain activity signals 16 (e.g., EEG) on a substantially continuous basis from the subject and analyze the brain activity signals in substantially real-time to estimate the subject's propensity for a seizure. If the observer algorithm determines that the subject has an elevated susceptibility for a seizure (e.g., seizure prediction—indicated in FIG. 5 as “Decision Made”), the duty cycling of the stimulation epochs 12 and data acquisition epochs 10 (as described above) may be initiated by the timing controller. In such embodiments, the duty cycling may follow a predetermined schedule (described above) or it may be adaptive to the subject's observed brain activity state.


The observer algorithms of the devices may be adapted to continue to analyze the discontinuous epochs of data to estimate the subject's susceptibility to a seizure while stimulation is initiated. By duty cycling the data acquisition and stimulation epochs, the seizure prediction and seizure detection devices are able to analyze the brain activity signals determine if the stimulation is effective in mitigating the subject's susceptibility to a seizure, while still reducing artifact in the sensed signals. While not shown in FIG. 5, if analysis of the discontinuous data acquisition epochs 10 shows that the subject no longer has an elevated susceptibility for a seizure, the device may be configured to revert back to the substantially continuous acquisition of brain activity signals 16 or a different duty cycle.


If however, the observer algorithm determines that the stimulation epochs have not reduced the subject's susceptibility for a seizure, a number of different actions could be carried out. First, the stimulation epochs may be continued using the same stimulation parameters and duty cycled with the data acquisition epochs. Second, one or more parameters of the duty cycling may be varied. For example, it may be useful to increase a duration of the stimulation epochs and/or reduce a duration of the data acquisition epochs and/or the epochs between the stimulation epoch and data acquisition epochs. Third, one or more parameters of the stimulation epoch may be automatically adaptively varied in an attempt to find a combination of parameters that are effective for the particular subject. If a certain combination of stimulation parameters are able to affect the subject's brain activity state better than other combinations of parameters, such parameters may be stored in memory and used for subsequent stimulation epochs.


The observer algorithm may be embodied in a device that is implanted in the subject, embodied in a device that is external to the subject, or in separate modules in both the implanted unit and external device. The observer algorithm may be used to analyze the subject's brain activity so as to determine the appropriate control signal, determine the subject's susceptibility to a seizure, predict/detect a seizure, and facilitate delivery of an appropriate electrical stimulation to the subject.



FIG. 6 illustrates one preferred embodiment in which the observer algorithm is in a device that is external to the subject. However, as described in pending commonly owned U.S. patent application Ser. Nos. 11/321,897 and 11/322,150, both filed Dec. 28, 2005, the observer algorithms of the present invention may be disposed anywhere within the system. In the embodiments in which the observer algorithm is external to the subject, the signals (EEG) are substantially continuously sampled by electrode arrays 9, 11 and sent to the sensing assembly in an implanted unit 24. The samples are subsequently transmitted to the external device 22 via the implanted unit 24.


The electrode arrays 9, 11 will be configured to sample the brain activity of the groups of neurons in the immediate vicinity of the electrode arrays 9, 11. The electrode arrays 9, 11 are electrically joined via cables 26 to the implanted unit 24. In one embodiment, the electrode arrays 9, 11 are implanted intracranially and the cables 26 are tunneled beneath the skin through the neck to the implanted unit 24 that is implanted in a subclavicular cavity of the subject. In alternative embodiments, the cables 26 and unit 24 may be attached to the subject externally.


In one embodiment, the implanted unit 24 is configured to facilitate the sampling of signals from the electrodes 9, 11. Sampling of brain activity is typically carried out at a rate above about 200 Hz, and preferably between about 200 Hz and about 1000 Hz, and most preferably at about 400 Hz. The sampling rates could be higher or lower, depending on the specific conditions being monitored, the subject, and other factors. Each sample of the subject's brain activity is typically encoded using between about 8 bits per sample and about 24 bits per sample, and preferably about 16 bits per sample.


In alternative embodiments, the implanted unit 24 may be configured to monitor the signals on a non-continuous basis. In such embodiments, signals may be monitored periodically or aperiodically.


The external data analysis/collection device 22 is preferably carried external to the body of the subject. The external device 22 can be a computer system, such as, e.g., a personal computer, handheld device, physician programmer, or the like. The external device 22 receives and stores signals, including EEG signals and possibly other physiological signals, from the implanted unit 24. Communication between the external data device 22 and the implanted unit 24 may be carried out through wireless communication, such as an infrared link, ultrasonic link, inductive link, radiofrequency link, or the like. The wireless communication link between the external data device 22 and the implanted unit 24 is typically a two-way communication link for transmitting data but could be a one-way communication link. For example, the external device and implanted unit could include both a two-way inductive link (short distance magnetic loop coupling) and a one-way RF link for sending alerts to the subject.


In alternative embodiments, it may be desirable to have a direct communications link from the external data device 22 to the implanted unit 24, such as, for example, via an interface device positioned below the subject's skin. The interface (not shown) may take the form of an adhesively or magnetically attached transducer that would enable power to be continuously delivered to the implanted unit 24 and would provide for relatively higher rates of data transmission. Error detection and correction methods may be used to help insure the integrity of transmitted data. If desired, the wireless data signals can be encrypted prior to transmission to the external data device 22.


The implanted unit 24 may optionally comprise electronic component systems as depicted schematically in FIG. 7. Energy for the system is supplied by a rechargeable power supply 28 (or a non-rechargeable power supply). The rechargeable power supply may be a battery, or the like. The rechargeable power supply 28 may also be in communication with a transmit/receive sub-system 30 so as to receive power from outside the body by inductive coupling, radiofrequency (RF) coupling, etc. Power supply 28 will generally be used to provide power to the other components of the implantable device. Signals 32 from the electrode array 9, 11 are received by sensing assembly 6 of the implanted unit 24. The signals may be initially conditioned by a signal conditioner 34 (e.g., an amplifier, a filter, and an analog-to-digital converter, etc.) and/or other signal processors 36 of the sensing assembly 6.


The amplifiers may be one or more single amplifiers or a multi-channel amplifiers depending upon the number of electrodes with which it interfaces. In some embodiments, the amplifiers are physically located in the same enclosure as the filters that is, in a single signal conditioner. The amplifiers may also be located separately from the filters. For example, the amplifier may be affixed to or situated adjacent to an associated electrode array. This arrangement facilitates the pre-amplification of the associated signals generated by the associated electrode arrays, which increases the signal-to-noise ratio of the acquired signals. The amplifiers may be any known voltage amplifier now or later developed suitable for amplifying the particular signals generated by an associated electrode or electrode array.


The amplified signal may then be passed to an associated filter. The filter can be physically separate from or incorporated into sensing assembly. The filter may be a low pass filter. The low pass filter typically has a cut-off frequency of 1000 Hz, preferably of 300 Hz, and most preferably of 150 Hz. In addition to or as an alternative to the low-pass filter, the device may include a notch filter to remove, for example, 50 or 60 Hz noise, or other types of filters appropriate for the type of signals acquired by an associated electrode arrays.


In preferred embodiments the sensing assembly also includes a signal processor or other dedicated hardware for further processing the conditioned signal. The signal processor can be implemented in, e.g., a fast microprocessor, a DSP (digital signal processor) chip, ASIC, or as analog circuitry. The signal processor (and any of the other signal processors described herein) may include multiple cores so as to improve processing throughput, while further reducing power consumption. The signal processor can include a separate signal processor for each conditioned signal which can be input if a plurality of electrodes acquire signal from the subject. Such signal processors may be used to filter, extract features from, transform, generate statistics for, or encrypt the sampled signals.


A memory module 38 may be provided for storage of some or all of the sampled signals prior to transmission via a transmit/receive sub-system 30 and antenna 40 to the external data device 22. For example, the memory module 40 may be used as a buffer to temporarily store the conditioned signals from the electrode arrays 9, 11 if there are problems with transmitting data to the external data device 22, such as may occur if the external data device 22 experiences power problems or is out of range of the communications system. The external data device 22 can be configured to communicate a warning signal to the subject in the case of data transmission problems to inform the subject and allow him or her to correct the problem. Memory module 38 may also be used to permanently store a portion or all of the sampled EEG signals, if desired.


The implanted unit 24 may optionally comprise dedicated circuitry of a digital or analog or combined digital/analog nature, ASIC, DSP and/or a fast microprocessor, referred to herein collectively as “processor” 42, for further processing the signals prior to transmission to the external data device 22. In some embodiments, the processor 42 may execute one or more observer algorithms such as, neurological event prediction or detection algorithms, seizure prediction algorithms, seizure detection algorithms, or portions of such algorithms. For example, in some configurations, the processor 42 may run one or more feature extractors that extract features from the EEG signal that are relevant to the purpose of monitoring. Thus, if the system is being used for diagnosing or monitoring epileptic subjects, the extracted features (either alone or in combination with other features) may be indicative or predictive of a seizure. Once the feature(s) are extracted, the processor 42 may transmit the extracted feature(s) to the external data device 22 and/or store the extracted feature(s) in memory 38. Because the transmission of the extracted features is likely to include less data than the EEG signal itself, such a configuration will likely reduce the bandwidth requirements for the communication link between the implanted unit 24 and the external data device 22.



FIG. 7 also illustrates some of the components that may be included in the external device 22. Signals from the implanted unit 24 are received at an antenna 50 and conveyed to a transmit/receive sub-system 52. The signals received may include a raw EEG signal, a processed EEG signal, extracted features from the EEG signal, a result from EEG analysis software that ran on the implanted processor 42, or any combination thereof.


The received data may thereafter be stored in memory 54, such as a hard drive, RAM, EEPROM, flash memory, or the like and/or processed by a microprocessor, ASIC, DSP, or other dedicated circuitry of a digital or analog or combined digital/analog nature, referred to herein collectively as a “processor” 56. Processor 56 may be configured to request that the implanted unit 24 perform various checks or calibrations prior to signal recording and/or at specified times to ensure the proper functioning of the system.


Data may be transmitted from memory 54 to processor 56 where the data may optionally undergo additional processing. For example, if the EEG data is encrypted, it may be decrypted. The processor 56 may also comprise one or more filters that filter out high-frequency artifacts (e.g., muscle movement artifacts, eye-blink artifacts, chewing, etc.) so as to prevent contamination of the high frequency components of the sampled EEG signals. In some embodiments, the processor 56 may process the EEG data to detect seizures, predict the onset of a future seizure, generate metrics/measurements of seizure activity, or the like as described below.


External data device 22 will typically include a user interface 60 for displaying outputs to the subject and for receiving inputs from the subject. The user interface will typically comprise outputs such as auditory devices (e.g., speakers) visual devices (e.g., LCD display), tactile devices (e.g., vibratory mechanisms), or the like, and inputs, such as a plurality of buttons, a touch screen, and/or a scroll wheel.


The user interface may be adapted to allow the subject to indicate and record certain events. For example, the subject may indicate that medication has been taken, the dosage, the type of medication, meal intake, sleep, drowsiness, occurrence of an aura, occurrence of a seizure, or the like. Such inputs may be used in conjunction with the recorded data to improve the off-line or on-line analysis of the subject's condition and determine the efficacy of the medications taken by the subject.


The LCD display may be used to output a variety of different communications to the subject including, status of the device (e.g., memory capacity remaining), battery state of one or more components of system, whether or not the external data device 22 is within communication range of the implanted unit 24, a warning (e.g., a seizure warning), a prediction (e.g., a seizure prediction), a recommendation (e.g., “take medicine”), or the like. Of course, it may be desirable to provide an audio output or vibratory output to the subject in addition to or as an alternative to the visual display on the LCD.


External data device 22 may also include a power source 62 or other conventional power supply that is in communication with at least one other component of external data device 22. The power source 62 may be rechargeable. If the power source 62 is rechargeable, the power source may optionally have an interface for communication with a charger 64. External data device 22 may also include a communication interface 66 for coupling to a remote computer 68 (e.g., a physician's computer workstation). While not shown in FIG. 7, external data device 22 will typically comprise a clock circuit (e.g., oscillator and frequency synthesizer) to provide the time base for synchronizing the external data device 22 and the implanted unit 24.


In a preferred embodiment, most or all of the processing of the signals received by the implanted unit 24 is done in an external data device 22 that is external to the subject's body. In such embodiments, the implanted unit 24 would receive the signals from subject and may or may not pre-process the signals and transmit some or all of the measured signals transcutaneously to an external data device 22, where the observer algorithm processes the EEG data. Advantageously, such embodiments reduce the amount of computational processing power that needs to be implanted in the subject, thus potentially reducing power consumption and increasing battery life. Furthermore, by having the processing external to the subject, the judgment or decision making components of the system may be more easily reprogrammed or custom tailored to the subject without having to reprogram the implanted unit 24.


In alternative embodiments, the observer algorithms disclosed herein and treatment algorithms responsive to the predictive algorithms may be embodied in a device that is implanted in the subject's body or the algorithm may be modular and some modules may be implanted in the subject's body and other modules may be external to the subject's body. For example, in one embodiment the observer algorithm may be stored in and processed by the implanted unit 24. A treatment algorithm, in contrast, may be processed in a processor that is embodied in an external data device 22 external to the subject's body. In such embodiments, the subject's propensity for seizure characterization (or whatever output is generated by the observer algorithm) is transmitted to the external device 22, and the processor performs any remaining processing to generate and display the output from the observer algorithm and communicate this to the subject. Such embodiments have the benefit of sharing processing power, while reducing the communications demands on the implanted unit 24. Furthermore, because the treatment algorithm is external to the subject, updating or reprogramming the treatment algorithm may be carried out more easily.


In other embodiments, the signals 32 may be processed in a variety of ways in the implanted unit 24 before transmitting data to the external data device 22 so as to reduce the total amount of data to be transmitted, thereby reducing the power demands of the transmit/receive sub-system 30. Examples include: digitally compressing the signals before transmitting them; selecting only a subset of the detected signals for transmission; selecting a limited segment of time and transmitting signals only from that time segment; extracting salient features of the signals and transmitting data representative of those features rather than the signals themselves. Further processing and analysis of the transmitted data may take place in the external data device 22.


It may be possible to perform some of the processing in the implanted unit 24 and some of the processing in the external data device 22. For example, one or more features from the one or more signals may be extracted with feature extractors in the implanted unit 24. Some or all of the extracted features may be transmitted to the external data device 22 where the features may be classified to predict the onset of a seizure, or the like. If desired, external data device 22 may be customizable to the individual subject. Consequently, the classifier may be adapted to allow for transmission or receipt of only the features from the implanted unit 24 that are predictive for that individual subject. Advantageously, by performing feature extraction in the implanted unit 24 and classification in an external device at least two benefits may be realized. First, the amount of wireless data transmitted from the implanted unit 24 to the external data device 22 is reduced (versus transmitting pre-processed data). Second, classification, which embodies the decision or judgment component, may be easily reprogrammed or custom tailored to the subject without having to reprogram the implanted unit 24.


In yet another embodiment, it may be possible to switch the positions of the classifier and the feature extractors so that feature extraction may be performed external to the body. Pre-processed signals (e.g., filtered, amplified, converted to digital) may be transcutaneously transmitted from implanted unit 24 to the external data device 22 where one or more features are extracted from the one or more signals with feature extractors. Some or all of the extracted features may be transcutaneously transmitted back into the implanted unit 24, where a second stage of processing may be performed on the features, such as classifying of the features (and other signals) to characterize the subject's propensity for the onset of a future seizure. If desired, to improve bandwidth, the classifier may be adapted to allow for transmission or receipt of only the features from the subject communication assembly that are predictive for that individual subject. Advantageously, because feature extractors may be computationally expensive and power hungry, it may be desirable to have the feature extractors external to the body, where it is easier to provide more processing and larger power sources.


The output from the observer algorithm (i.e., brain activity state measurement, “yes” seizure, “no” seizure, normal susceptibility, elevated susceptibility, etc.) may be used by a control assembly 18 of the timing controller 4 to initiate duty cycling, adjust parameters of the duty cycling, and/or determine the parameters of a subsequent neuromodulation signal transmitted to the subject (if any). For example, the control assembly 18 may be adapted to adjust the acquisition epochs and/or stimulation epochs from the acquisition epochs and/or stimulation epochs programmed into the timing controller 4 for the duty cycle.


As noted above, the control assembly 18 can also be adapted to dynamically adjust the stimulation and/or acquisition epochs of the duty cycle. Dynamic adjustments to the timing controller can be accomplished using the closed-loop feedback system described herein. The sensing assembly can acquire a signal from the subject indicative of the subject's brain activity response to a previously delivered stimulation signal. Based on the acquired signal, or parameters thereof, the control assembly can dynamically adjust any of the timing parameters stored in the timing controller, e.g., the duty cycle of the acquisition and/or stimulation epoch.


In alternative embodiments of the present invention, one of the signal processors 42, 56 of the system may include at least one observer algorithm which is configured to be controlled by the timing controller to run and process data acquired by, e.g., an electrode array, at a specified time or times.


In some configurations, the observer algorithm is configured to be controlled by the timing controller 4 to process signal data only at specified times. The times at which such processing occurs can be synchronized with the time at which a sensing electrode array is acquiring a signal from the subject, such that a signal is acquired by the subject and the corresponding signal is received and processed by the observer algorithm to generate an output. The observer algorithm will thus be controlled by the timing controller not to run and process data at specified times. The sensing electrode array can again be synchronized not to acquire any signal from the subject during the time at which the observer algorithm is not running and processing data. Thus, in some embodiments, the sensing electrode array and the observer algorithm can be controlled to be operating at substantially the same time. Controlling when these components are operating and thus receiving power from the system helps control the system's power consumption and can increase the life of the system.


It is further contemplated that one or more of the components of the sensing assembly can also be configured to be controlled by the timing controller 4 to run/operate at specified times. In such embodiments the one or more components can be controlled to run at the same, substantially the same or different times depending on the component. For example, it may be advantageous for the sensing electrode array to acquire a signal from the subject, but rather than analyze the sampled signals immediately, to store the acquired signal in memory module 38, 54 until a later time when the observer algorithm can process the data. For example, a sensing electrode array could be controlled to acquire a signal from a subject based on a specified duty cycle, while the observer algorithm is controlled to process data based on a different duty cycle the sensing electrode.


The control assembly 18 receives an output from the observer algorithm, e.g., a neural state of the subject, seizure prediction, susceptibility to seizure, etc. The control assembly 18 is configured to then determine and/or adjust parameter(s) of the stimulation signal to be delivered to the subject. The stimulation signal to be generated, as determined by the control assembly, is output to the stimulation assembly 8, including the signal generator which generates the stimulation signal. In one embodiment, the control assembly is a state machine, utilizing current and past system behavior in the determination and calculation of a stimulation signal.


The control assembly may calculate waveform parameters of the stimulation signal to be delivered, including, e.g., pulse amplitude, pulse width, pulse frequency, pulses per burst, and burst frequency. Alternatively, the waveform parameters may already be predetermined based on prior physician input. The control assembly can also select between the regulation of pulse voltage or pulse current as the regulated pulse amplitude.


The stimulation assembly 8, shown in FIGS. 1 and 7, receives the output from the control assembly 18. The stimulation assembly 8 can comprise a pulse generator 44 and signal conditioner 46 (e.g., an output amplifier, therapy power supply, output multiplexer, DC balancing or blocking circuit or the like). The pulse generator generates, based on the output received from the control assembly, one or more stimulus waveforms, each of which is characterized by several parameters, e.g., pulse amplitude, pulse width, pulse frequency, number of pulses per burst, and burst frequency. As noted above, pulse amplitude may comprise pulse voltage or pulse current. Preferably, each of these parameters can be independently varied, as specified by the output from the control assembly. As noted, the stimulus waveforms comprising the stimulation signal generated by the stimulation assembly are applied to the subject via the electrode array. The pulse generator generates a single waveform when single channel stimulation is to be used, and a plurality of waveforms when multiple channel stimulation is to be used. The pulse generator may generate monophasic, biphasic waveforms, or multiphasic waveforms, with or without DC current and deliver such waveforms to the stimulation electrode array. The stimulation waveforms may be delivered directly to the brain tissue (e.g., epidural, subdural, deep brain tissue, etc.), to cranial nerves, peripheral nerves, and/or to other nervous system or non-nervous system components.


While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention For example, while preferred embodiments incorporate a timing controller, alternate embodiments of the present invention may not include a central timing controller, and the stimulation may be designed to always have sufficient inactive epochs between stimulation epochs, and the sensing assembly of the system of the present invention can determine on its own when stimulation artifact is causing a problem and disqualify that portion of the signal, (e.g., the sensing assembly will have the capability to determine when stimulation is not occurring).


It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.

Claims
  • 1. A system to reduce artifact in a signal acquired from a subject, the system comprising: a sensing assembly adapted to acquire a signal from a subject indicative of the subject's brain activity;a stimulation assembly adapted to stimulate one or more neurons of the subject; anda timing controller programmed to control the time the sensing assembly is powered to acquire the signal such that the sensing assembly is powered at a substantially different time than the time when the stimulation assembly stimulates the subject and that the sensing assembly is not powered to acquire the signal during the time the stimulation assembly stimulates the subject,wherein the acquisition time and the stimulation time are variable based upon the subject's predicted susceptibility to having a seizure.
  • 2. The system of claim 1 wherein the timing controller is programmed to control the time at which the sensing assembly acquires the signal to be multiple discrete acquisition times and to control the time at which the stimulation assembly stimulates the one or more neurons to be multiple discrete stimulation times.
  • 3. The system of claim 2 wherein the timing controller is programmed to control the sensing assembly to acquire the signal in between the stimulation assembly stimulating the one or more neurons.
  • 4. The system of claim 2 wherein each of the multiple discrete acquisition times are about 0.25 seconds to about 5 minutes.
  • 5. The system of claim 4 wherein each of the multiple discrete acquisition times are about 1 second to about 30 seconds.
  • 6. The system of claim 2 wherein each of the multiple discrete stimulation times are about 0.5 seconds to about 5 minutes.
  • 7. The system of claim 6 wherein each of the multiple discrete stimulation times are about 1 second to about 30 seconds.
  • 8. The system of claim 2 wherein the system further comprises a control assembly adapted to adjust the multiple discrete acquisition times and the multiple discrete stimulation times.
  • 9. The system of claim 8 wherein the control assembly is in communication with a device external to the subject, wherein the device is adapted to allow adjustment of the stimulation and acquisition times.
  • 10. The system of claim 8 wherein the control assembly is adapted to dynamically adjust the stimulation or acquisition times.
  • 11. The system of claim 1 wherein the acquisition time and the stimulation time provide an epoch of time between the acquisition time and stimulation time in which no acquisition or stimulation occurs.
  • 12. The system of claim 11 wherein each epoch of time between the acquisition times and stimulation times in which no acquisition or stimulation occurs is about 0.25 seconds to about 10 seconds.
  • 13. The system of claim 12 wherein each epoch of time between the acquisition times and stimulation times in which no acquisition or stimulation occurs is about 1 second to about 5 seconds.
  • 14. The system of claim 1 wherein the sensing assembly and the stimulation assembly each comprise an electrode array.
  • 15. The system of claim 14 wherein the same electrode array is used to stimulate the one or more neurons and acquire the signal from the subject.
  • 16. The system of claim 14 wherein the stimulation assembly comprises an electrode array adapted to be coupled to a peripheral nerve.
  • 17. The system of claim 16 wherein the peripheral nerve is a vagus nerve.
  • 18. The system of claim 1 wherein the signal is an EEG signal from the subject.
  • 19. The system of claim 1 wherein the subject's brain activity is analyzed to predict an onset of a seizure.
  • 20. The system of claim 1 further comprising a signal processor in communication with the sensing assembly adapted to process the signal to estimate an epileptic neural state.
  • 21. The system of claim 20 wherein the signal processor comprises an observer algorithm operative when the sensing assembly is acquiring the signal.
  • 22. The system of claim 21 wherein the observer algorithm comprises one or more feature extractors and a classifier.
  • 23. The system of claim 1 wherein the timing controller is programmed to increase a parameter of the stimulation when the subject has a predicted elevated susceptibility for having a seizure.
  • 24. The system of claim 23 wherein the timing controller is programmed to increase the stimulation frequency when the subject has a predicted elevated susceptibility for having a seizure.
  • 25. The system of claim 1 wherein the timing controller is programmed to initiate stimulation when the subject has a predicted elevated susceptibility for having a seizure.
  • 26. The system of claim 1 wherein the timing controller is programmed to decrease a parameter of the stimulation when the subject has a predicted reduced susceptibility for having a seizure.
  • 27. A method of reducing artifact in a signal acquired from a subject, the method comprising: powering signal acquisition circuitry to acquire a signal from a subject indicative of the subject's brain activity;stimulating the subject;controlling the time during which the powering signal acquisition circuitry occurs such that the signal acquisition circuitry is powered at a substantially different time than the time during which stimulating the subject occurs and that the signal acquisition circuitry is not powered to acquire the signal during said stimulating the subject; andvarying the acquiring time and the stimulating time based upon the subject's predicted susceptibility to having a seizure.
  • 28. The method of claim 27 wherein the powering comprises acquiring the signal at multiple discrete acquisition times and the stimulating comprises stimulating the one or more neurons at multiple discrete stimulation times.
  • 29. The method of claim 28 wherein the powering occurs between the stimulating the subject.
  • 30. The method of claim 29 further comprising adjusting the multiple discrete acquisition times and/or the multiple discrete stimulation times.
  • 31. The method of claim 28 wherein each of the multiple discrete acquisition times are about 0.25 seconds to about 5 minutes.
  • 32. The method of claim 31 wherein each of the multiple discrete acquisition times are about 1 to about 30 seconds.
  • 33. The method of claim 28 wherein each of the multiple discrete stimulation times are about 0.5 seconds to about 5 minutes.
  • 34. The method of claim 33 wherein the multiple discrete stimulation times are about 1 to about 30 seconds.
  • 35. The method of claim 28 wherein the acquiring comprises acquiring an EEG signal from the subject.
  • 36. The method of claim 28 wherein the stimulating comprises stimulating a peripheral nerve.
  • 37. The method of claim 36 wherein the peripheral nerve is a vagus nerve.
  • 38. The method of claim 28 wherein the subject's brain activity is processed to measure the subject's susceptibility to a seizure.
  • 39. The method of claim 28 further comprising processing the signal to estimate an epileptic neural state.
  • 40. The method of claim 28 wherein each epoch of time between acquisition times and stimulation times in which no acquisition or stimulation occurs is about 0.25 seconds to about 10 seconds.
  • 41. The method of claim 40 wherein each epoch of time between acquisition times and stimulation times in which no acquisition or stimulation occurs is about 1 second to about 5 seconds.
  • 42. The method of claim 27 wherein the varying step comprises increasing a stimulating parameter based upon a predicted elevated susceptibility to having a seizure.
  • 43. The method of claim 42 wherein increasing a stimulating parameter based upon an elevated predicted susceptibility to having a seizure comprises increasing the stimulation frequency based upon a predicted elevated susceptibility to having a seizure.
  • 44. The method of claim 27 wherein the varying step comprises initiating stimulation based upon a predicted elevated susceptibility to having a seizure.
  • 45. The method of claim 27 wherein the varying step comprises decreasing a stimulation parameter based upon a predicted reduced susceptibility to having a seizure.
  • 46. A method of managing seizures, the method comprising: acquiring an EEG signal from a subject during multiple discrete acquisition times;stimulating one or more neurons of the subject during multiple discrete stimulation times;controlling the time during which signal acquisition circuitry is powered to acquire the EEG signal such that the signal acquisition circuitry is powered at a substantially different time than the time during which the stimulating occurs and that the signal acquisition circuitry is not powered to acquire the EEG signal during the time the stimulating occurs; andvarying the acquisition times and the stimulation times based upon the subject's predicted susceptibility to having a seizure.
  • 47. The method of claim 46 wherein the varying step comprises increasing a stimulating parameter based upon a predicted elevated susceptibility to having a seizure.
  • 48. The method of claim 46 wherein the varying step comprises decreasing a stimulating parameter based upon a predicted reduced susceptibility to having a seizure.
  • 49. The method of claim 46 wherein each of the multiple discrete acquisition times are about 0.25 seconds to about 5 minutes.
  • 50. The method of claim 49 wherein each of the multiple discrete acquisition times are about 1 to about 30 seconds.
  • 51. The method of claim 46 wherein each of the multiple discrete stimulation times are about 0.5 seconds to about 5 minutes.
  • 52. The method of claim 51 wherein each of the multiple discrete stimulation times are about 1 to about 30 seconds.
  • 53. The method of claim 46 wherein epochs of time between acquisition times and stimulation times in which no acquisition or stimulation occurs are about 0.25 seconds to about 10 seconds each.
  • 54. The method of claim 53 wherein epochs of time between acquisition times and stimulation times in which no acquisition or stimulation occurs are about 1 second to about 5 seconds each.
US Referenced Citations (496)
Number Name Date Kind
3218638 Honig Nov 1965 A
3498287 Ertl Mar 1970 A
3522811 Schwartz Aug 1970 A
3575162 Gaarder Apr 1971 A
3837331 Ross Sep 1974 A
3850161 Liss Nov 1974 A
3863625 Viglione et al. Feb 1975 A
3882850 Bailin et al. May 1975 A
3918461 Cooper Nov 1975 A
3967616 Ross Jul 1976 A
3993046 Fernandez Nov 1976 A
4201224 John May 1980 A
4214591 Sato et al. Jul 1980 A
4279258 John Jul 1981 A
4305402 Katims Dec 1981 A
4334545 Shiga Jun 1982 A
4407299 Culver Oct 1983 A
4408616 Duffy et al. Oct 1983 A
4421122 Duffy Dec 1983 A
4471786 Inagaki Sep 1984 A
4494950 Fischell Jan 1985 A
4505275 Chen Mar 1985 A
4545388 John Oct 1985 A
4556061 Barreras et al. Dec 1985 A
4566464 Piccone et al. Jan 1986 A
4573481 Bullara Mar 1986 A
4579125 Strobl et al. Apr 1986 A
4590946 Loeb May 1986 A
4612934 Borkan Sep 1986 A
4679144 Cox et al. Jul 1987 A
4686999 Snyder et al. Aug 1987 A
4702254 Zabara Oct 1987 A
4735208 Wyler et al. Apr 1988 A
4768176 Kehr et al. Aug 1988 A
4768177 Kehr et al. Aug 1988 A
4785827 Fischer Nov 1988 A
4793353 Borkam Dec 1988 A
4817628 Zealear Apr 1989 A
4838272 Lieber Jun 1989 A
4844075 Liss et al. Jul 1989 A
4852573 Kennedy Aug 1989 A
4867164 Zabara Sep 1989 A
4873981 Abrams et al. Oct 1989 A
4878498 Abrams et al. Nov 1989 A
4903702 Putz Feb 1990 A
4920979 Bullara May 1990 A
4926865 Oman May 1990 A
4955380 Edell Sep 1990 A
4978680 Sofia Dec 1990 A
4979511 Terry Dec 1990 A
4991582 Byers et al. Feb 1991 A
5010891 Chamoun Apr 1991 A
5016635 Graupe May 1991 A
5025807 Zabara Jun 1991 A
5031618 Mullett Jul 1991 A
5070873 Graupe et al. Dec 1991 A
5082861 Sofia Jan 1992 A
5097835 Putz Mar 1992 A
RE34015 Duffy Aug 1992 E
5154172 Terry Oct 1992 A
5167229 Peckham et al. Dec 1992 A
5179950 Stanislaw Jan 1993 A
5181520 Wertheim et al. Jan 1993 A
5186170 Varichio Feb 1993 A
5188104 Wernicke Feb 1993 A
5190029 Byron et al. Mar 1993 A
5193539 Schulman et al. Mar 1993 A
5193540 Schulman et al. Mar 1993 A
5205285 Baker, Jr. Apr 1993 A
5215086 Terry, Jr. et al. Jun 1993 A
5215088 Normann Jun 1993 A
5215089 Baker, Jr. Jun 1993 A
5222494 Baker, Jr. Jun 1993 A
5222503 Ives Jun 1993 A
5231988 Wernicke et al. Aug 1993 A
5235980 Varichio et al. Aug 1993 A
5237991 Baker, Jr. Aug 1993 A
5251634 Weinberg Oct 1993 A
5263480 Wernicke et al. Nov 1993 A
5265619 Comby et al. Nov 1993 A
5269302 Swartz et al. Dec 1993 A
5269303 Wernicke et al. Dec 1993 A
5269315 Leuchter et al. Dec 1993 A
5292772 Sofia Mar 1994 A
5293879 Vonk Mar 1994 A
5299118 Martens et al. Mar 1994 A
5299569 Wernicke et al. Apr 1994 A
5300094 Kallok et al. Apr 1994 A
5304206 Baker, Jr. et al. Apr 1994 A
5311876 Olsen et al. May 1994 A
5312439 Loeb May 1994 A
5314458 Najafi et al. May 1994 A
5324316 Schulman et al. Jun 1994 A
5330515 Rutecki et al. Jul 1994 A
5335657 Terry et al. Aug 1994 A
5342408 deColriolis et al. Aug 1994 A
5342409 Mullett Aug 1994 A
5343064 Spangler et al. Aug 1994 A
5349962 Lockard et al. Sep 1994 A
5351394 Weinberg Oct 1994 A
5361760 Normann Nov 1994 A
5365939 Ochs Nov 1994 A
5376359 Johnson Dec 1994 A
5392788 Hudspeth Feb 1995 A
5405365 Hoegnelid et al. Apr 1995 A
5405367 Schulman et al. Apr 1995 A
5411540 Edell et al. May 1995 A
5458117 Chamoun Oct 1995 A
5474547 Aebischer et al. Dec 1995 A
5476494 Edell et al. Dec 1995 A
5486999 Mebane Jan 1996 A
5513649 Gevins May 1996 A
5531778 Maschino et al. Jul 1996 A
5540730 Terry Jul 1996 A
5540734 Zabara Jul 1996 A
5549656 Reiss Aug 1996 A
5555191 Hripcsak Sep 1996 A
5571148 Loeb et al. Nov 1996 A
5571150 Wernicke Nov 1996 A
5575813 Edell et al. Nov 1996 A
5578036 Stone et al. Nov 1996 A
5611350 John Mar 1997 A
5626145 Clapp et al. May 1997 A
5626627 Krystal et al. May 1997 A
5638826 Wolpaw Jun 1997 A
5649068 Boser et al. Jul 1997 A
5672154 Sillen et al. Sep 1997 A
5683422 Rise Nov 1997 A
5683432 Goedeke et al. Nov 1997 A
5690681 Geddes et al. Nov 1997 A
5690691 Chen et al. Nov 1997 A
5697369 Long Dec 1997 A
5700282 Zabara Dec 1997 A
5704352 Tremblay et al. Jan 1998 A
5707400 Terry et al. Jan 1998 A
5711316 Elsberry et al. Jan 1998 A
5713923 Ward et al. Feb 1998 A
5715821 Faupel Feb 1998 A
5716377 Rise et al. Feb 1998 A
5720294 Skinner Feb 1998 A
5735814 Elsberry et al. Apr 1998 A
5743860 Hively et al. Apr 1998 A
5752979 Benabid May 1998 A
5769778 Abrams et al. Jun 1998 A
5776434 Purewal et al. Jul 1998 A
5782798 Rise Jul 1998 A
5782874 Loos Jul 1998 A
5782891 Hassler et al. Jul 1998 A
5792186 Rise Aug 1998 A
5800474 Bernabid et al. Sep 1998 A
5813993 Kaplan Sep 1998 A
5814014 Elsberry et al. Sep 1998 A
5815413 Hively et al. Sep 1998 A
5816247 Maynard Oct 1998 A
5824021 Rise Oct 1998 A
5832932 Elsberry et al. Nov 1998 A
5833709 Rise et al. Nov 1998 A
5857978 Hively et al. Jan 1999 A
5862803 Besson et al. Jan 1999 A
5876424 O'Phelan et al. Mar 1999 A
5899922 Loos May 1999 A
5913881 Benz et al. Jun 1999 A
5916239 Geddes et al. Jun 1999 A
5917429 Otis, Jr. et al. Jun 1999 A
5928272 Adkins Jul 1999 A
5931791 Saltzstein et al. Aug 1999 A
5938689 Fischell et al. Aug 1999 A
5941906 Barreras et al. Aug 1999 A
5950632 Reber et al. Sep 1999 A
5957861 Combs et al. Sep 1999 A
5971594 Sahai et al. Oct 1999 A
5975085 Rise Nov 1999 A
5978702 Ward et al. Nov 1999 A
5978710 Prutchi et al. Nov 1999 A
5995868 Dorfmeister et al. Nov 1999 A
6006124 Fischell et al. Dec 1999 A
6016449 Fischell et al. Jan 2000 A
6018682 Rise Jan 2000 A
6042548 Giuffre Mar 2000 A
6042579 Elsberry et al. Mar 2000 A
6051017 Loeb et al. Apr 2000 A
6052619 John Apr 2000 A
6061593 Fischell et al. May 2000 A
6066163 John May 2000 A
6081744 Loos Jun 2000 A
6094598 Elsberry et al. Jul 2000 A
6109269 Rise et al. Aug 2000 A
6117066 Abrams et al. Sep 2000 A
6128537 Rise et al. Oct 2000 A
6128538 Fischell et al. Oct 2000 A
6134474 Fischell et al. Oct 2000 A
6161045 Fischell et al. Dec 2000 A
6167304 Loos Dec 2000 A
6171239 Humphrey Jan 2001 B1
6176242 Rise Jan 2001 B1
6205359 Boveja Mar 2001 B1
6208893 Hofmann Mar 2001 B1
6221011 Bardy Apr 2001 B1
6227203 Rise et al. May 2001 B1
6230049 Fischell et al. May 2001 B1
6248126 Lesser et al. Jun 2001 B1
6249703 Stanton Jun 2001 B1
6263237 Rise Jul 2001 B1
6280198 Calhoun et al. Aug 2001 B1
6304775 Iasemidis et al. Oct 2001 B1
6309406 Jones et al. Oct 2001 B1
6328699 Eigler Dec 2001 B1
6337997 Rise Jan 2002 B1
6339725 Naritoku Jan 2002 B1
6341236 Osorio et al. Jan 2002 B1
6343226 Sunde et al. Jan 2002 B1
6353754 Fischell et al. Mar 2002 B1
6354299 Fischell et al. Mar 2002 B1
6356784 Lozano et al. Mar 2002 B1
6356788 Boveja Mar 2002 B2
6358203 Bardy Mar 2002 B2
6358281 Berrang et al. Mar 2002 B1
6360122 Fischell Mar 2002 B1
6366813 DiLorenzo Apr 2002 B1
6366814 Boveja Apr 2002 B1
6374140 Rise Apr 2002 B1
6386882 Linberg May 2002 B1
6402678 Fischell et al. Jun 2002 B1
6411854 Tziviskos et al. Jun 2002 B1
6427086 Fischell et al. Jul 2002 B1
6434419 Gevins et al. Aug 2002 B1
6442421 Quyen et al. Aug 2002 B1
6443891 Grevious Sep 2002 B1
6453198 Torgerson Sep 2002 B1
6463328 John Oct 2002 B1
6466822 Pless Oct 2002 B1
6471645 Warkentin et al. Oct 2002 B1
6473639 Fischell et al. Oct 2002 B1
6473644 Terry et al. Oct 2002 B1
6480743 Kirkpatrick Nov 2002 B1
6484132 Hively et al. Nov 2002 B1
6488617 Katz Dec 2002 B1
6496724 Levendowski et al. Dec 2002 B1
6505077 Kast et al. Jan 2003 B1
6510340 Jordan Jan 2003 B1
6511424 Moore-Ede Jan 2003 B1
6529774 Greene Mar 2003 B1
6534693 Fischell et al. Mar 2003 B2
6547746 Marino Apr 2003 B1
6549804 Osorio et al. Apr 2003 B1
6553262 Lang et al. Apr 2003 B1
6560486 Osorio et al. May 2003 B1
6571123 Ives et al. May 2003 B2
6571125 Thompson May 2003 B2
6572528 Rohan et al. Jun 2003 B2
6587719 Barrett et al. Jul 2003 B1
6591132 Gotman et al. Jul 2003 B2
6591137 Fischell et al. Jul 2003 B1
6591138 Fischell et al. Jul 2003 B1
6597954 Fischell et al. Jul 2003 B1
6600956 Maschino Jul 2003 B2
6609025 Barrett et al. Aug 2003 B2
6618623 Pless et al. Sep 2003 B1
6620415 Donovan Sep 2003 B2
6622036 Suffin Sep 2003 B1
6622038 Barrett et al. Sep 2003 B2
6622041 Terry et al. Sep 2003 B2
6622047 Barrett et al. Sep 2003 B2
6658287 Litt et al. Dec 2003 B1
6665562 Gluckman et al. Dec 2003 B2
6668191 Boveja Dec 2003 B1
6671555 Gielen Dec 2003 B2
6678548 Echauz et al. Jan 2004 B1
6684105 Cohen et al. Jan 2004 B2
6687538 Hrdlicka et al. Feb 2004 B1
6735467 Wilson May 2004 B2
6760626 Boveja Jul 2004 B1
6768969 Nikitin et al. Jul 2004 B1
6778854 Puskas Aug 2004 B2
6782292 Whitehurst Aug 2004 B2
6879859 Boveja Apr 2005 B1
6893395 Kraus et al. May 2005 B1
6901294 Whitehurst et al. May 2005 B1
6901296 Whitehurst et al. May 2005 B1
6912419 Hill Jun 2005 B2
6921538 Donovan Jul 2005 B2
6921541 Chasin et al. Jul 2005 B2
6923784 Stein Aug 2005 B2
6931274 Williams Aug 2005 B2
6934580 Osorio Aug 2005 B1
6937891 Leinders et al. Aug 2005 B2
6944501 Pless Sep 2005 B1
6950706 Rodriguez Sep 2005 B2
6973342 Swanson Dec 2005 B1
6990372 Perron et al. Jan 2006 B2
7010351 Firlik et al. Mar 2006 B2
7089059 Pless Aug 2006 B1
7117108 Rapp et al. Oct 2006 B2
7174212 Klehn et al. Feb 2007 B1
7177701 Pianca Feb 2007 B1
7209787 DiLorenzo Apr 2007 B2
7212851 Donoghue et al. May 2007 B2
7231254 DiLorenzo Jun 2007 B2
7324851 DiLorenzo Jan 2008 B1
7373198 Bibian et al. May 2008 B2
7463917 Martinez Dec 2008 B2
7631015 Gupta et al. Dec 2009 B2
7805196 Miesel et al. Sep 2010 B2
7881798 Miesel et al. Feb 2011 B2
8055348 Heruth et al. Nov 2011 B2
20010051819 Fischell et al. Dec 2001 A1
20010056290 Fischell et al. Dec 2001 A1
20020002390 Fischell et al. Jan 2002 A1
20020035338 Dear et al. Mar 2002 A1
20020054694 Vachtsevanos et al. May 2002 A1
20020072770 Pless Jun 2002 A1
20020072776 Osorio et al. Jun 2002 A1
20020072782 Osorio et al. Jun 2002 A1
20020077670 Archer et al. Jun 2002 A1
20020095099 Quyen et al. Jul 2002 A1
20020099412 Fischell et al. Jul 2002 A1
20020103512 Echauz et al. Aug 2002 A1
20020109621 Khair et al. Aug 2002 A1
20020111542 Warkentin et al. Aug 2002 A1
20020116042 Boling Aug 2002 A1
20020126036 Flaherty et al. Sep 2002 A1
20020147388 Mass et al. Oct 2002 A1
20020169485 Pless et al. Nov 2002 A1
20020177882 DiLorenzo Nov 2002 A1
20020188330 Gielen et al. Dec 2002 A1
20030004428 Pless Jan 2003 A1
20030009207 Paspa et al. Jan 2003 A1
20030013981 Gevins et al. Jan 2003 A1
20030018367 DiLorenzo Jan 2003 A1
20030028072 Fischell et al. Feb 2003 A1
20030050549 Sochor Mar 2003 A1
20030050730 Greeven et al. Mar 2003 A1
20030073917 Echauz et al. Apr 2003 A1
20030074033 Pless et al. Apr 2003 A1
20030083716 Nicolelis et al. May 2003 A1
20030114886 Gluckman et al. Jun 2003 A1
20030144709 Zabara et al. Jul 2003 A1
20030144711 Pless et al. Jul 2003 A1
20030144829 Geatz et al. Jul 2003 A1
20030149457 Tcheng et al. Aug 2003 A1
20030158587 Esteller et al. Aug 2003 A1
20030167078 Weisner et al. Sep 2003 A1
20030174554 Dunstone et al. Sep 2003 A1
20030176806 Pineda et al. Sep 2003 A1
20030181955 Gielen Sep 2003 A1
20030187621 Nikitin et al. Oct 2003 A1
20030195574 Osorio et al. Oct 2003 A1
20030195588 Fischell et al. Oct 2003 A1
20030195602 Boling Oct 2003 A1
20040034368 Pless et al. Feb 2004 A1
20040039427 Barrett et al. Feb 2004 A1
20040039981 Riedl et al. Feb 2004 A1
20040054297 Wingeier et al. Mar 2004 A1
20040059761 Hively Mar 2004 A1
20040068199 Echauz et al. Apr 2004 A1
20040073273 Gluckman et al. Apr 2004 A1
20040077995 Ferek-Petric Apr 2004 A1
20040078160 Frei et al. Apr 2004 A1
20040082984 Osorio et al. Apr 2004 A1
20040087835 Hively May 2004 A1
20040097802 Cohen May 2004 A1
20040122281 Fischell et al. Jun 2004 A1
20040122335 Sackellares et al. Jun 2004 A1
20040127810 Sackellares et al. Jul 2004 A1
20040133119 Osorio et al. Jul 2004 A1
20040133248 Frei et al. Jul 2004 A1
20040133390 Osorio et al. Jul 2004 A1
20040138516 Osorio et al. Jul 2004 A1
20040138517 Osorio et al. Jul 2004 A1
20040138536 Frei et al. Jul 2004 A1
20040138578 Pineda et al. Jul 2004 A1
20040138579 Deadwyler et al. Jul 2004 A1
20040138580 Frei et al. Jul 2004 A1
20040138581 Frei et al. Jul 2004 A1
20040138647 Osorio et al. Jul 2004 A1
20040138711 Osorio et al. Jul 2004 A1
20040138721 Osorio et al. Jul 2004 A1
20040147969 Mann et al. Jul 2004 A1
20040152958 Frei et al. Aug 2004 A1
20040153129 Pless et al. Aug 2004 A1
20040158119 Osorio et al. Aug 2004 A1
20040172089 Whitehurst et al. Sep 2004 A1
20040176359 Wermeling Sep 2004 A1
20040181263 Balzer et al. Sep 2004 A1
20040199212 Fischell Oct 2004 A1
20040210269 Shalev et al. Oct 2004 A1
20040243146 Chesbrough et al. Dec 2004 A1
20040267152 Pineda et al. Dec 2004 A1
20050004621 Boveja et al. Jan 2005 A1
20050010261 Luders et al. Jan 2005 A1
20050015128 Rezai et al. Jan 2005 A1
20050015129 Mische Jan 2005 A1
20050021103 DiLorenzo Jan 2005 A1
20050021104 DiLorenzo Jan 2005 A1
20050021105 Firlik et al. Jan 2005 A1
20050021108 Klosterman et al. Jan 2005 A1
20050021313 Nikitin et al. Jan 2005 A1
20050027328 Greenstein Feb 2005 A1
20050033369 Badelt Feb 2005 A1
20050043772 Stahmann et al. Feb 2005 A1
20050043774 Devlin et al. Feb 2005 A1
20050049649 Luders et al. Mar 2005 A1
20050059867 Cheng Mar 2005 A1
20050070970 Knudson et al. Mar 2005 A1
20050075067 Lawson et al. Apr 2005 A1
20050096710 Kieval May 2005 A1
20050113885 Haubrich et al. May 2005 A1
20050119703 DiLorenzo Jun 2005 A1
20050124863 Cook Jun 2005 A1
20050131493 Boveja et al. Jun 2005 A1
20050137640 Freeberg et al. Jun 2005 A1
20050143786 Boveja Jun 2005 A1
20050143787 Boveja et al. Jun 2005 A1
20050149123 Lesser et al. Jul 2005 A1
20050182308 Bardy Aug 2005 A1
20050182464 Schulte et al. Aug 2005 A1
20050187789 Hatlestad Aug 2005 A1
20050197590 Osorio et al. Sep 2005 A1
20050203366 Donoghue et al. Sep 2005 A1
20050203584 Twetan et al. Sep 2005 A1
20050209218 Meyerson et al. Sep 2005 A1
20050222503 Dunlop et al. Oct 2005 A1
20050222626 DiLorenzo Oct 2005 A1
20050222641 Pless Oct 2005 A1
20050228249 Boling Oct 2005 A1
20050228461 Osorio et al. Oct 2005 A1
20050231374 Diem et al. Oct 2005 A1
20050234355 Rowlandson Oct 2005 A1
20050240245 Bange et al. Oct 2005 A1
20050245970 Erickson et al. Nov 2005 A1
20050245971 Brockway et al. Nov 2005 A1
20050245984 Singhal et al. Nov 2005 A1
20050266301 Smith et al. Dec 2005 A1
20050277844 Strother Dec 2005 A1
20060015034 Martinerie et al. Jan 2006 A1
20060015153 Gliner et al. Jan 2006 A1
20060094970 Drew May 2006 A1
20060111644 Guttag et al. May 2006 A1
20060122469 Martel Jun 2006 A1
20060129056 Leuthardt et al. Jun 2006 A1
20060142822 Tulgar Jun 2006 A1
20060173259 Flaherty et al. Aug 2006 A1
20060173510 Besio et al. Aug 2006 A1
20060200038 Savit et al. Sep 2006 A1
20060212092 Pless et al. Sep 2006 A1
20060212093 Pless et al. Sep 2006 A1
20060212096 Stevenson Sep 2006 A1
20060217792 Hussein et al. Sep 2006 A1
20060224191 Dilorenzo Oct 2006 A1
20060253096 Blakley et al. Nov 2006 A1
20060293578 Rennaker, II Dec 2006 A1
20060293720 DiLorenzo et al. Dec 2006 A1
20070027367 Oliver et al. Feb 2007 A1
20070027514 Gerber Feb 2007 A1
20070035910 Stevenson Feb 2007 A1
20070043459 Abbott, III et al. Feb 2007 A1
20070055320 Weinand Mar 2007 A1
20070060973 Ludvig et al. Mar 2007 A1
20070073355 DiLorenzo Mar 2007 A1
20070073357 Rooney et al. Mar 2007 A1
20070100398 Sloan May 2007 A1
20070142862 DiLorenzo Jun 2007 A1
20070149952 Bland et al. Jun 2007 A1
20070150024 Leyde et al. Jun 2007 A1
20070150025 DiLorenzo et al. Jun 2007 A1
20070161919 DiLorenzo Jul 2007 A1
20070162086 DiLorenzo Jul 2007 A1
20070167991 DiLorenzo Jul 2007 A1
20070185890 VanEpps et al. Aug 2007 A1
20070213629 Greene Sep 2007 A1
20070213785 Osorio et al. Sep 2007 A1
20070217121 Fu et al. Sep 2007 A1
20070238939 Giftakis et al. Oct 2007 A1
20070244407 Osorio Oct 2007 A1
20070250077 Skakoon et al. Oct 2007 A1
20070250901 McIntire et al. Oct 2007 A1
20070287931 DiLorenzo Dec 2007 A1
20080021341 Harris et al. Jan 2008 A1
20080027347 Harris et al. Jan 2008 A1
20080027348 Harris et al. Jan 2008 A1
20080027515 Harris et al. Jan 2008 A1
20080033502 Harris et al. Feb 2008 A1
20080082019 Ludving et al. Apr 2008 A1
20080091090 Guillory et al. Apr 2008 A1
20080103556 Li et al. May 2008 A1
20080161712 Leyde Jul 2008 A1
20080161713 Leyde et al. Jul 2008 A1
20080221876 Holdrich Sep 2008 A1
20080319281 Aarts Dec 2008 A1
20090264952 Jassemidis et al. Oct 2009 A1
20100023089 DiLorenzo Jan 2010 A1
20100125219 Harris et al. May 2010 A1
20100145176 Himes Jun 2010 A1
20110166430 Harris et al. Jul 2011 A1
20110260855 John et al. Oct 2011 A1
20110319785 Snyder et al. Dec 2011 A1
Foreign Referenced Citations (100)
Number Date Country
2251852 Apr 1999 CA
2423840 Feb 2002 CA
2428116 May 2002 CA
2428383 May 2002 CA
2425122 Jun 2002 CA
2425004 Aug 2002 CA
2456443 Jan 2003 CA
2491987 Jan 2004 CA
69832022D Dec 2005 DE
0124663 Nov 1984 EP
0898460 Mar 1999 EP
1017313 Jul 2000 EP
1107693 Jun 2001 EP
1145735 Oct 2001 EP
1145736 Oct 2001 EP
1292900 Mar 2003 EP
1307260 May 2003 EP
1331967 Aug 2003 EP
1335668 Aug 2003 EP
1341580 Sep 2003 EP
1404216 Apr 2004 EP
1333753 Sep 2004 EP
1525551 Apr 2005 EP
1558121 Aug 2005 EP
1558128 Aug 2005 EP
1558130 Aug 2005 EP
1558131 Aug 2005 EP
1558132 Aug 2005 EP
1558330 Aug 2005 EP
1558334 Aug 2005 EP
1562674 Aug 2005 EP
0911061 Oct 2005 EP
1609414 Dec 2005 EP
24033673 Feb 2004 JP
1074484 Feb 1984 SU
WO 8501213 Mar 1985 WO
WO 9200119 Jan 1992 WO
WO 9726823 Jul 1997 WO
WO 9734522 Sep 1997 WO
WO 9734524 Sep 1997 WO
WO 9734525 Sep 1997 WO
WO 9739797 Oct 1997 WO
WO 9742990 Nov 1997 WO
WO 9745160 Dec 1997 WO
WO 9849935 Nov 1998 WO
WO 9920342 Apr 1999 WO
WO 9956821 Nov 1999 WO
WO 9956822 Nov 1999 WO
WO 0007494 Feb 2000 WO
WO 0010455 Mar 2000 WO
WO 0141867 Jun 2001 WO
WO 0148676 Jul 2001 WO
WO 0149364 Jul 2001 WO
WO 0167288 Sep 2001 WO
WO 0175660 Oct 2001 WO
WO 0209610 Feb 2002 WO
WO 0209811 Feb 2002 WO
WO 0236003 May 2002 WO
WO 0238031 May 2002 WO
WO 0238217 May 2002 WO
WO 0249500 Jun 2002 WO
WO 02058536 Aug 2002 WO
WO 02067122 Aug 2002 WO
WO 03001996 Jan 2003 WO
WO 03009207 Jan 2003 WO
WO 03030734 Apr 2003 WO
WO 03035165 May 2003 WO
WO 03084605 Oct 2003 WO
WO 2004008373 Jan 2004 WO
WO 2004032720 Apr 2004 WO
WO 2004034231 Apr 2004 WO
WO 2004034879 Apr 2004 WO
WO 2004034880 Apr 2004 WO
WO 2004034881 Apr 2004 WO
WO 2004034882 Apr 2004 WO
WO 2004034883 Apr 2004 WO
WO 2004034885 Apr 2004 WO
WO 2004034982 Apr 2004 WO
WO 2004034997 Apr 2004 WO
WO 2004034998 Apr 2004 WO
WO 2004035130 Apr 2004 WO
WO 2004036370 Apr 2004 WO
WO 2004036372 Apr 2004 WO
WO 2004036376 Apr 2004 WO
WO 2004036377 Apr 2004 WO
WO 2004037342 May 2004 WO
WO 2004043536 May 2004 WO
WO 2004091718 Oct 2004 WO
WO 2005007236 Jan 2005 WO
WO 2005028026 Mar 2005 WO
WO 2005028028 Mar 2005 WO
WO 2005031630 Apr 2005 WO
WO 2005051167 Jun 2005 WO
WO 2005051306 Jun 2005 WO
WO 2005117693 Dec 2005 WO
WO 2006014971 Feb 2006 WO
WO 2006014972 Feb 2006 WO
WO 2006020794 Feb 2006 WO
WO 2006035392 Apr 2006 WO
WO 2007150003 Dec 2007 WO
Related Publications (1)
Number Date Country
20080114417 A1 May 2008 US